PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.
Completed
- Conditions
- Blood Coagulation
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 553
- Registration Number
- NCT00775398
Study Evaluating Changes In Mammographic Breast Density
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 507
- Registration Number
- NCT00774267
- Locations
- 🇳🇴
Pfizer Investigational Site, Hamar, Norway
A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin
Phase 1
Completed
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00774605
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3939
- Registration Number
- NCT00772941
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Other: Cohort
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 851
- Registration Number
- NCT00770289
- Locations
- 🇬🇷
Pfizer Investigational Site, Ilissia, Athens, Greece
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Drug: chemotherapy
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00768755
- Locations
- 🇬🇧
Pfizer Investigational Site, Poole, United Kingdom
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT00768664
- Locations
- 🇨🇦
Hopital Notre-dame du CHUM - Oncology Center, Montreal, Quebec, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Study Evaluating the Nasopharyngeal Carriage in Healthy Children
Completed
- Conditions
- Healthy Subjects
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 242
- Registration Number
- NCT00768833
- Locations
- 🇩🇪
Pfizer Investigational Site, Offenbach, Germany
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT00769067
- Locations
- 🇵🇱
Medex spolka cywilna, Chrzanow, Poland
🇪🇸Hospital de Cruces, Barakaldo, Vizcaya, Spain
🇵🇱"Vesalius" Sp. z o.o., Krakow, Poland
Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media
Completed
- Conditions
- Otitis Media
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2138
- Registration Number
- NCT00768534
- Locations
- 🇩🇪
Dr. Andreas Busse, Tegernsee, Bavarian, Germany
© Copyright 2025. All Rights Reserved by MedPath